These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 682811)

  • 41. FDA community meeting May 16: clinical trials and viral load. Food and Drug Administration.
    AIDS Treat News; 1997 May; (No 270):3. PubMed ID: 11364324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bioavailability and bioequivalence requirements; abbreviated applications; proposed revisions--FDA. Proposed rule.
    Fed Regist; 1998 Nov; 63(223):64222-8. PubMed ID: 10339051
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FDA requests comments on IDE regulations.
    FDA Drug Bull; 1986 Nov; 16(2):18. PubMed ID: 3817346
    [No Abstract]   [Full Text] [Related]  

  • 44. FDA issues regulations on accelerated drug-approval process.
    Clin Pharm; 1993 Apr; 12(4):253-4. PubMed ID: 8458175
    [No Abstract]   [Full Text] [Related]  

  • 45. Investigational new drug application; exception from informed consent; technical amendment--FDA. Final rule.
    Fed Regist; 1997 Jun; 62(115):32479. PubMed ID: 10169828
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Delegations of authority and organization; Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1993 Apr; 58(61):17093-4. PubMed ID: 10125229
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of regulations on artificial organs research.
    Morton WA; DeVries WC; Dobelle WH; Serkes KD; Sheridan R; Dennis C
    Trans Am Soc Artif Intern Organs; 1983; 29():770-3. PubMed ID: 6673323
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Revocation of regulation on positron emission tomography drug products--FDA. Final rule; revocation.
    Fed Regist; 1997 Dec; 62(244):66522. PubMed ID: 10179303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delegations of authority and organization--FDA. Final rule.
    Fed Regist; 1993 Apr; 58(61):17091-3. PubMed ID: 10125228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FDA considers tightening regulations for direct-to-consumer advertising.
    Vastag B
    J Natl Cancer Inst; 2005 Dec; 97(24):1806-7. PubMed ID: 16368941
    [No Abstract]   [Full Text] [Related]  

  • 51. Content and format for labeling for human prescription drugs; amendment of effective date for certain biological products--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(15 pt 1):7271-3. PubMed ID: 10249526
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring; extension of comment period--FDA. Proposed rule; extension of comment period.
    Fed Regist; 1998 Aug; 63(148):41219-20. PubMed ID: 10181522
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Delegations of authority and organization; Center for Devices and Radiological Health--FDA. Final rule.
    Fed Regist; 1994 Jun; 59(116):31138. PubMed ID: 10136908
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Viral load: inconclusive FDA hearing. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 244):5. PubMed ID: 11363306
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protection of human subjects; informed consent--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(17 pt 2):8942-58. PubMed ID: 10249528
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The use of FM amplification instruments for infants and preschool children with hearing impairment. Committee on Amplification for the Hearing Impaired American Speech-Language-Hearing Association.
    ASHA Suppl; 1991 Mar; (5):1-2. PubMed ID: 1673599
    [No Abstract]   [Full Text] [Related]  

  • 57. Removal of regulations regarding certification of antibiotic drugs; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(91):26127-9. PubMed ID: 10179335
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Removal of regulations regarding certification of drugs composed wholly or partly of insulin--FDA. Direct final rule.
    Fed Regist; 1998 May; 63(92):26694-9. PubMed ID: 10179341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medical devices; humanitarian use of devices--FDA. Final rule.
    Fed Regist; 1998 Nov; 63(212):59217-22. PubMed ID: 10187383
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Consequences and implications to FDA regulations of immune modulation by chemicals.
    McCurdy JD
    Prog Clin Biol Res; 1984; 161():401-2. PubMed ID: 6483897
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.